‘If you've ever experienced it, you'd feel differently’: Exploring willingness and skepticism toward using higher dose naloxone products among people who use drugs in Maryland, United States
Addiction · 2026-09 · 121 (9) · 2494-2503
DOI: 10.1111/add.70447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Addiction, online erschienen am 29.04.2026. Verfasst von Laura N Sisson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Naloxone, Narcotic Antagonists, Drug Overdose, Opioid-Related Disorders. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Bloomberg American Health Initiative.
Abstract (Originalsprache)
Background and aims Higher dose naloxone products (HDN) have recently been approved and marketed in the United States; however, evidence on the relative advantage of these products to standard 4 mg products has not been substantiated by prior research. People who use drugs are the primary beneficiaries and consumers of naloxone products. This study aimed to characterize their willingness to use HDN products and technical understanding of these products. Design and measurements We conducted in‐depth interviews with syringe service program clients following an interview guide. Interviews were recorded and transcribed before being analyzed using a hybrid deductive‐inductive qualitative approach.
Setting
Interviews were conducted in partnership with community‐based syringe service programs in three distinct regions of the state of Maryland, USA: a rural county, Baltimore city and a surrounding suburban community.
Participants
Twenty‐two interviews were completed. All participants had used opioids and responded to an overdose using naloxone in the past 3 months. The majority of participants were men (73%), non‐Hispanic white (64%) and currently experiencing housing instability (59%).
Findings
Participants demonstrated high willingness to use HDN, motivated by volatility in the local drug supply and perceived inefficiency of naloxone against potent synthetic opioids. Participants believed that the relative advantage of HDN was that it would reverse overdoses more quickly than existing products; however, many participants wanted increased control in overdose situations, including the ability to titrate and combine dosages to reduce the severity of precipitated withdrawal. Skepticism towards HDN products was rooted in general skepticism of pharmaceutical companies, as well as the belief that perceptions of lower dose naloxone being ineffective could be attributed to user error.
Conclusions
Development of novel overdose reversal products should be informed by the experiences of primary consumers and beneficiaries of these products. A high level of transparency is needed in the marketing of these products to promote consumer trust and confidence in their safety and utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
- Department of Health, Behavior and Society, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
- School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
- College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
- College of Global Public Health, New York University, New York, NY, USA.
ORCID-Profile: Laura N Sisson, Lucas G Hill
Förderung
- Bloomberg American Health Initiative
Zitieren
APA
Sisson, L. N., Rousch, R. S., Hill, L. G., Zagorski, C. M., Triece, T., Rouhani, S., Owczarzak, J., Sherman, S. G., & Schneider, K. E. (2026). ‘If you've ever experienced it, you'd feel differently’: Exploring willingness and skepticism toward using higher dose naloxone products among people who use drugs in Maryland, United States. Addiction, 121(9), 2494-2503. https://doi.org/10.1111/add.70447
Vancouver
Sisson LN, Rousch RS, Hill LG, Zagorski CM, Triece T, Rouhani S, et al. ‘If you've ever experienced it, you'd feel differently’: Exploring willingness and skepticism toward using higher dose naloxone products among people who use drugs in Maryland, United States. Addiction. 2026;121(9):2494-2503. doi:10.1111/add.70447
BibTeX
@article{Sisson2026,
author = {Sisson, Laura N and Rousch, Richard S and Hill, Lucas G and Zagorski, Claire M and Triece, Tricia and Rouhani, Saba and Owczarzak, Jill and Sherman, Susan G and Schneider, Kristin E},
title = {‘If you've ever experienced it, you'd feel differently’: Exploring willingness and skepticism toward using higher dose naloxone products among people who use drugs in Maryland, United States},
journal = {Addiction},
year = {2026},
volume = {121},
number = {9},
pages = {2494--2503},
doi = {10.1111/add.70447}
}
EUVIMED